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Objective: The aim was to evaluate, in patients with atrial fibrillation (AF) and acute ischemic stroke, the association of
prior anticoagulation with vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) with stroke severity, utili-
zation of intravenous thrombolysis (IVT), safety of IVT, and 3-month outcomes.
Methods: This was a cohort study of consecutive patients (2014–2019) on anticoagulation versus those without (con-
trols) with regard to stroke severity, rates of IVT/mechanical thrombectomy, symptomatic intracranial hemorrhage
(sICH), and favorable outcome (modified Rankin Scale score 0–2) at 3 months.
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Results: Of 8,179 patients (mean [SD] age, 79.8 [9.6] years; 49% women), 1,486 (18%) were on VKA treatment, 1,634
(20%) on DOAC treatment at stroke onset, and 5,059 controls. Stroke severity was lower in patients on DOACs
(median National Institutes of Health Stroke Scale 4, [interquartile range 2–11]) compared with VKA (6, [2–14]) and con-
trols (7, [3–15], p < 0.001; quantile regression: β −2.1, 95% confidence interval [CI] −2.6 to −1.7). The IVT rate in poten-
tially eligible patients was significantly lower in patients on VKA (156 of 247 [63%]; adjusted odds ratio [aOR] 0.67; 95%
CI 0.50–0.90) and particularly in patients on DOACs (69 of 464 [15%]; aOR 0.06; 95% CI 0.05–0.08) compared with con-
trols (1,544 of 2,504 [74%]). sICH after IVT occurred in 3.6% (2.6–4.7%) of controls, 9 of 195 (4.6%; 1.9–9.2%; aOR 0.93;
95% CI 0.46–1.90) patients on VKA and 2 of 65 (3.1%; 0.4–10.8%, aOR 0.56; 95% CI 0.28–1.12) of those on DOACs.
After adjustments for prognostic confounders, DOAC pretreatment was associated with a favorable 3-month outcome
(aOR 1.24; 1.01–1.51).
Interpretation: Prior DOAC therapy in patients with AF was associated with decreased admission stroke severity at
onset and a remarkably low rate of IVT. Overall, patients on DOAC might have better functional outcome at 3 months.
Further research is needed to overcome potential restrictions for IVT in patients taking DOACs.
ANN NEUROL 2021;89:42–53
Oral anticoagulation with direct oral anticoagulants(DOACs) or vitamin K antagonists (VKAs) is highly
efficacious in the prevention of acute ischemic stroke in
patients with atrial fibrillation (AF).1–3 Nevertheless,
ischemic stroke occurs in ~2% of patients on anticoagu-
lants per year,4,5 and ~10% of all ischemic stroke patients
are already on anticoagulation therapy at stroke onset.6,7
Prior therapeutic VKA and DOAC therapy has been
associated with reduced stroke severity at onset as mea-
sured using the National Institutes of Health Stroke Scale
(NIHSS).8–11 Acute recanalization therapies (intravenous
thrombolysis [IVT] and mechanical thrombectomy [MT])
are the cornerstone of acute stroke therapy, improving
functional outcome and preventing major disability after
stroke.12 Prior anticoagulation is a relative contraindica-
tion for IVT12 and a risk–benefit judgment is usually
made on MT according to current American heart associa-
tion/American stroke association (AHA/ASA) guidelines.
The results from observational studies suggest that IVT
and MT are safe in selected patients taking VKAs (if INR
is ≤1.7)13,14 and DOACs.13,15–19 However, prior anti-
coagulation therapy poses a major challenge in the hyper-
acute setting owing to the fear of an increased risk of
symptomatic intracranial hemorrhage (sICH). In particu-
lar, prior DOAC therapy might represent a major barrier
to the use of acute recanalization therapies because of
uncertainties surrounding the monitoring of drug effects.
Therefore, the benefits of prior DOAC therapy on acute
stroke characteristics might conversely be canceled out by
poorer long-term functional outcomes owing to a reluc-
tance to use acute recanalization therapies.
We aimed to assess the rate of prior treatment with
VKAs or DOACs in patients with AF and acute ischemic
stroke in a national dataset and determine its association
with: (1) stroke severity and the presence of large vessel
occlusion (LVO) at onset, (2) use of acute recanalization
therapies and incidence of their complications (sICH),
and (3) functional outcome at 3 months.
Patients and Methods
Study Population and Setting
This is an analysis of data from the Swiss Stroke Registry
(SSR), a compulsory prospectively constructed national
registry. Since 2014, all consecutive patients hospitalized
in stroke units and comprehensive stroke centers (all certi-
fied according to national Swiss Stroke Unit and Stroke
Center criteria, and in line with those of the European
Stroke Organisation)20 have been enrolled in the SSR,
which is designed for quality control and research in acute
stroke management.21,22 For the present analysis, we
included all consecutive ischemic stroke patients with AF
(AF diagnosed either before or after stroke onset) aged
≥18 years who were admitted from January 2014 to
October 2019 to hospitals participating in the SSR. We
excluded patients with missing data on prior anti-
coagulation therapy.
This project was planned, designed, and approved
by the SSR steering committee, which is composed of
multidisciplinary researchers (neurology, neuroradiology,
and neurosurgery) in cooperation with the clinical trials
units of Basel (data management) and Bern (data
analysis).
Baseline Characteristics
Local investigators at the participating SSR centers col-
lected standardized and prespecified variables using elec-
tronic case report forms. The secured, web-based
databank is hosted by the clinical trials unit in Basel. The
following variables were used in this analysis: patient
demographic characteristics (age, sex, and body mass
index), medical history (eg, history of prior ischemic
stroke, intracerebral hemorrhage, hypertension, dys-
lipidemia, diabetes, AF, and smoking), prior anti-
coagulation therapy on admission (no
anticoagulation = controls, VKA, or DOAC), clinical
information (NIHSS score, blood glucose, and blood pres-
sure on admission, and international normalized ratio
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[INR] for patients taking VKA), in addition to the diag-
nostic tests performed (eg, imaging modality, presence of
LVO). Information on recanalization treatments included
the use of IVT and/or MT plus details on dose, workflow
metrics, and mode of application. We collected additional
information from every stroke center and stroke unit on:
(1) availability of a standard operating procedure for IVT
and MT in patients on DOACs, (2) availability and turn-
around time (median, estimate) of drug-specific coagula-
tion assays for DOACs plasma levels,23 (3) availability and
local standard operating procedure for use of drug-specific
reversal agents for DOACs (ie, idarucizumab and
andexanet alfa) before IVT or MT in patients taking
DOACs, and (4) reasons to withhold IVT in patients on
DOACs potentially eligible for IVT.24,25 A plausibility
check was applied, including restrictions for age, NIHSS,
blood pressure, body mass index, and symptom onset to
hospital time (see data analysis plan in the Online Supple-
ment), and data items were set as missing if they were
implausible.
Prior Anticoagulation Therapy
Patients with prior anticoagulation therapy were defined
as those on prescribed anticoagulation therapy at the time
of stroke symptom onset. For this analysis, anticoagulation
treatments were categorized into three mutually exclusive
groups: (1) controls (patients with AF without anti-
coagulation), (2) VKA, and (3) DOACs (rivaroxaban,
dabigatran, apixaban, or edoxaban). For sensitivity
analysis, we divided the VKA group into patients with
confirmed therapeutic (admission INR >1.7) and non-
therapeutic (INR ≤1.7, ie, not within the therapeutic
range) drug treatment. Patients with other types of anti-
coagulation, such as heparins, were also excluded from this
analysis, whereas additional prescription of antiplatelet
agents had no effect on group allocation.
Follow-Up and Outcomes
All patients enrolled in the SSR received standardized
follow-up assessments by local investigators for in-hospital
(sICH according to ECASS-II criteria [an intracranial
hemorrhage was defined as symptomatic if the patient had
clinical deterioration causing an increase in the NIHSS
score of more than or equal to 4 points and if the hemor-
rhage was likely to be the cause of the clinical deteriora-
tion]) and 3-month outcomes (functional outcome using
the modified Rankin Scale score [mRS]). All follow-up
checks were performed by mRS-certified stroke neurolo-
gists or trained research staff during clinic visits, or by
structured telephone interviews conducted by mRS-
certified examiners.
The main outcomes for this analysis were: (1) stroke
severity at admission (NIHSS), (2) presence of LVO,
(3) rates of IVT and MT, (4) occurrence of symptomatic
intracranial hemorrhage (ECASS-II definition), and
(5) favorable functional outcome at 3 months (mRS 0–2).
See Fig 1 for flow diagram of outcome completeness.
Statistical Analysis
The statistical analysis followed a predefined statistical
analysis plan (T.R.M., M.B., and D.J.S.). We used the
median (interquartile range [IQR]) or mean (standard
deviation [SD]), as appropriate, and percentages, to pre-
sent the distribution of continuous, ordinal, and categori-
cal variables, respectively. We compared the baseline
characteristics across the prior anticoagulation treatment
groups using the Pearson χ2 test for categorical variables
and the Kruskal–Wallis test for continuous and ordinal
variables.
For the primary analysis, we used univariate and
multiple regression models to investigate the association
between prior anticoagulation therapy and the main out-
comes (NIHSS at onset; rates of IVT, MT, and sICH;
and favorable outcome at 3 months). Prior anticoagulation
was included as an independent variable, with controls
(patients with AF without anticoagulation) as the reference
group, and prior VKAs and DOACs as the other categori-
cal groups. All analyses were performed on the cohort of
ischemic stroke patients with AF unless otherwise
indicated.
To assess the association of the NIHSS and presence
of LVO at stroke onset with prior anticoagulation therapy,
the following covariates were included in a quantile
(NIHSS) or binary multiple (LVO) regression model: age,
sex, admission glucose, previous ischemic stroke, previous
transient ischemic attack, arterial hypertension, diabetes
mellitus, dyslipidemia, smoking, and systolic blood
pressure.
To analyze the association of prior anticoagulation
and acute recanalization therapies (IVT and MT) with the
complication (sICH), we restricted the analysis to patients
who were potentially eligible for acute recanalization ther-
apies. For questions in potentially IVT-eligible patients,
we included patients presenting 0 to 4.5 hours after symp-
tom onset and excluded patients with INR >1.7, platelet
count <100g/l, admission glucose <2.7or >22.2mmol/l,
NIHSS <4, and patients with a history of intracerebral
hemorrhage before the current ischemic stroke onset. For
MT, we included patients presenting 0 to 6 hours after
symptom onset and with a NIHSS ≥6. We present the
rate of IVT, MT, and sICH with 95% confidence inter-
vals (CI) and relevant procedural metrics (door-to-needle
and door-to-groin-puncture time). We performed
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univariate comparisons of factors associated with receiving
IVT and MT. To assess the association between IVT and
prior anticoagulation therapy, we performed univariate
comparisons and applied a stepwise multiple regression
model to identify factors associated with receiving IVT.
To assess the association between prior anti-
coagulation and functional outcome at 3 months, we per-
formed two multivariate models. Initially, we adjusted a
basic model for prespecified baseline confounders includ-
ing age, sex, admission NIHSS, and use of IVT and
MT. In an additional advanced model, we adjusted for
admission glucose (1 if >7.3 or <3.7mmol/l; 0 if 3.7–
7.3mmol/l), onset to admission time (1 if >3 hours from
symptom onset to admission; 0 if 0–3 hours), previous
ischemic stroke, previous intracerebral hemorrhage, arterial
hypertension, diabetes mellitus, and systolic blood pres-
sure (1 if >180 or <140mmHg; 0 if 140–180mmHg).
Patients with missing outcome measures or missing data
items were excluded from the multivariable analysis. For
the interaction analysis between prior anticoagulation
treatment, IVT, and 3-month functional outcome, we
included an interaction term of IVT eligibility and anti-
coagulation in the logistic regression model.
We performed the following post-hoc sensitivity
analyses. To determine the relationship between NIHSS
and LVO, we used mediation analysis using the Stata
gformula function. Furthermore, as we assumed that
DOACs protect against severe stroke, a lower admission
NIHSS would be a covariate on the pathway of causality
between DOAC pretreatment and 3-month outcome;
therefore, adjusting for admission NIHSS might constitute
an over-adjustment. Therefore, we repeated the
multivariate analysis without NIHSS. Furthermore, we
included pre-stroke mRS in the model to adjust for prior
disability. Finally, we repeated the multivariate models
using ordinal shift analysis instead of dichotomized mRS
at 3 months.
We calculated (adjusted) odds ratios (aORs) and the
corresponding 95% CI. All statistical analyses were per-
formed using STATA (StataCorp. 2019. Stata Statistical
Software: Release 16. College Station, TX: StataCorp
LLC). All p-values are 2-sided, with p < .05 considered
statistically significant, and without adjustments for multi-
ple testing.
Ethics
The registry and this analysis were both approved by the
responsible ethics committee (KEK Bern 2019-01010). In
accordance with Swiss law, patients who, after being
informed about the collection of their biological data,
refused to allow its use for research purposes were




Of all 38,632 patients with ischemic stroke admitted to
13 certified Swiss stroke units and 10 stroke centers
between January 5, 2014 and October 8, 2019, 8,179
(21.2%) had pre-existing or newly diagnosed AF (mean
[SD] age, 79.8 [9.6] years; 49% women; median NIHSS
6). Ninety-five of 38,632 patients (0.25%) were excluded
because of missing information on prior anticoagulation
therapy. Among all stroke patients, 2,472 patients (6.4%)
FIGURE 1: Flow diagram of outcome completeness. AF = atrial fibrillation; IVT = intravenous thrombolysis; LVO = large vessel
occlusion; mRS = modified Rankin Scale; MT = mechanical thrombectomy; NIHSS = National Institutes of Health Stroke Scale;
sICH = symptomatic intracranial hemorrhage.
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had prior DOAC treatment and 2,368 patients (6.1%)
prior VKA treatment. Among ischemic stroke patients
with AF, 1,486 (18%) patients had received preceding
VKA and 1,634 (20%) preceding DOAC treatment
(rivaroxaban 1,040, apixaban 408, dabigatran 99 and
edoxaban 87), with decreasing rates of VKA and increas-
ing rates of DOACs over time, whereas 5,059 (62%) were
controls (Fig 2). Of the VKA-treated patients, 609 (41%)
had a subtherapeutic therapy (INR ≤1.7). Among the
ischemic stroke patients with AF potentially eligible for
IVT, 466 (18%) had prior DOAC treatment and
247 (9.5%) prior VKA treatment, with rapidly increasing
numbers of DOAC pretreatment in recent years
(see Fig 2).
Ischemic stroke patients with AF showed baseline
differences in age, medical history of ischemic stroke, tran-
sient ischemic attack, hypertension, diabetes mellitus, dys-
lipidemia, smoking, symptom onset-to-hospital time, and
systolic and diastolic blood pressures (Table 1). Owing to
missing data items, 98% of patients were included in the
basic and 82% in the advanced multiple regression
models.
Stroke Severity and Presence of Large Vessel
Occlusion at Onset
Information on stroke severity at onset was available for
98% of patients (n = 8,025). Patients on DOACs had a
lower stroke severity score (NIHSS median 4, IQR
[2–11]) than patients on VKA (6 [2–14]) and controls
(7 [3–15], p < 0.001; Table 2) in unadjusted analysis.
Stroke was less severe in patients on therapeutic VKA
(5 [2–12]) compared with those outside the therapeutic
range (8 [3–16], p < 0.001). After adjustments for con-
founders, in comparison to controls, stroke was more
severe (β indicates the median difference in NIHSS score)
in patients with subtherapeutic VKA (β 1.4, 95% CI 0.1–
2.6, p = 0.031) and less severe in those with therapeutic
values of VKA (β −1.8, 95% CI −2.5 to −1.1,
p < 0.001) and in patients on DOACs (β −2.1, 95% CI
−2.6 to −1.7, p < 0.001). When comparing all patients
on VKA regardless of INR, stroke was milder (β −0.9,
95% CI −1.5 to −0.3, p = 0.004) than in controls, but
even less severe in patients on DOACs (β −2.1, 95% CI
−2.5 to −1.7, p < 0.001). LVO was present in 51% of
controls, 44% of patients on VKA, and 39% of those on
DOACs (p < 0.001). After adjustment for confounders,
LVO occurred less often in patients on VKAs (aOR 0.81,
95% CI 0.70–0.93) and DOACs (aOR 0.67, 95% CI
0.58–0.76) than in controls. LVO was also less frequent
in patients on DOACs than in those on VKA (aOR 0.82,
95% CI 0.69–0.99, p = 0.038). The post-hoc mediation
analysis showed that presence of LVO accounted for 77%
(95% CI 64–91%, p < 0.001) of NIHSS severity.
Acute Recanalization Therapies: IVT, MT,
and sICH
Information on IVT, MT, and sICH was available for
99% (IVT and MT) and 98% (sICH, n = 8,026) of
patients, respectively. Among patients potentially eligible
for IVT, the rate of IVT was 1,544 of 2,504 (74%; 95%
CI 72–76%) in controls, 156 of 247 (63%; 57–69%) in
patients on VKA (with INR ≤1.7), and 69 of 464 (15%;
12–18%) in patients on DOACs. Patients on prior anti-
coagulation therapy had longer door-to-needle times, with
FIGURE 2: Frequency of prior anticoagulation treatment in patients with ischemic stroke. (A) Percentages of patients with atrial
fibrillation among all ischemic stroke patients. (B) Percentages of patients with atrial fibrillation within the subgroup of ischemic
stroke patients potentially eligible for intravenous thrombolysis. Note the decrease in VKA pretreatment with concomitant rapid
increase in DOAC pretreatment in both patient groups. DOACs = direct oral anticoagulants; IVT = intravenous thrombolysis;
VKA = vitamin K antagonist.
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a time delay of 15 minutes in patients on VKA and
14 minutes in patients on DOACs in comparison to con-
trols (p < 0.001; Table 2). Among patients on DOAC
therapy receiving IVT, 59 (86%) were treated at a stroke
center and 10 (15%) at a stroke unit. sICH after IVT
occurred in 49 of 1,363 (3.6%; 2.6–4.7%) controls, 9 of
195 (4.6%; 1.9–9.2%) patients on VKA with INR ≤1.7,
and 2 of 65 (3.1%; 0.4–10.8%, p = 0.796) patients on
DOACs (Table 2). After adjustment for confounders,
there was no difference in the occurrence of sICH
between patients on VKAs with INR ≤1.7 (aOR 1.6,
0.8–3.1) or on DOACs (aOR 0.6 (0.2–1.6) and controls.
Among patients potentially eligible for MT (presenting
≤6 hours after symptom onset, with NIHSS ≥6), the rate
of MT was 43% (95% CI 40–45%) in controls, 42%
(36–49%) in patients on VKAs with INR ≤1.7, and 43%
(38–48%) in those on DOACs (p = 0.951). There was
also no significant time delay in symptom onset-to-groin-
puncture in patients on VKAs (mean 371 minutes) and
DOACs (375 minutes) compared with controls
(364 minutes, p = 0.685).
Among all 23 certified stroke units and stroke cen-
ters, 21 (91%) had a standard operating procedure to
select patients on DOACs for IVT and MT that included
prespecified selection criteria (ie, time since last intake,
drug-specific coagulation assay, and nonspecific coagula-
tion assays). Most centers (18 of 21, 86%) used drug-
specific coagulation assays (ie, calibrated anti-Xa activity
for apixaban, edoxaban, or rivaroxaban; or thrombin time
for dabigatran), which apply previously published cut-off
values for IVT.15,26 Among centers making drug-specific
coagulation measurements, the estimated turnaround time
for these assays (ie, time from blood sampling to first
results available) was <60 minutes for 16 of 18 (89%) and










All (n = 1,486)
INR
≤1.7 (n = 609)
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>1.7 (n = 877)
DOACs
(n = 1,634) pa













Sex, male n = 8,173, 4207
(51%)
n = 5,055, 2,558
(51%)
n = 1,485, 766
(52%)
n = 608, 279
(46%)
n = 877, 487
(56%)




















n = 8,100, 1784
(22%)
n = 4,998, 847
(17%)
n = 1,473, 401
(27%)
n = 602, 163
(27%)
n = 871, 238
(27%)





n = 8,093, 578
(7%)
n = 4,998, 281
(6%)
n = 1,470, 146
(10%)
n = 599, 46
(8%)
n = 871, 100
(11%)





n = 8,101, 195
(2%)
n = 5,000, 131
(3%)
n = 1,474, 31
(2%)
n = 603, 12
(2%)
n = 871, 19
(2%)
n = 1,627, 33
(2%)
0.281
Hypertension, yes n = 8,132, 6,823
(84%)




n = 605, 545
(90%)





Diabetes mellitus, yes n = 8,127, 1,868
(23%)
n = 5,016, 1,060
(21%)
n = 1,480, 406
(27%)
n = 604, 165
(27%)
n = 876, 241
(28%)
n = 1,631, 402
(25%)
<0.001
Dyslipidemia, yes n = 8,079, 5,001
(62%)
n = 4,990, 2,975
(60%)
n = 1,469, 964
(66%)
n = 600, 384
(64%)





Smoker, yes n = 8,020, 978
(12%)
n = 4,932, 649
(13%)
n = 1,469, 140
(10%)
n = 602, 49
(8%)
n = 867, 91
(10%)
n = 1,619, 189
(12%)
0.001















INR value n = 1450, 1.9
(1.5; 2.4)
n = 609, 1.4
(1.2; 1.6)
n = 841, 2.3
(2.0; 2.8)











































aUnivariate comparison between controls, all vitamin K antagonists and DOACs.
aAF = atrial fibrillation; DOACs = direct oral anticoagulants; INR = international normalized ratio.
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<30 minutes for 5 of 18 (28%) centers. Eighteen of
23 centers (78%) reported that their internal guidelines
include evaluation of the use of specific reversal agents (ie,
idarucizumab for dabigatran, or andexanet alfa for
apixaban or rivaroxaban) in selected patients on DOACs
before IVT (or MT). Andexanet alfa was not available in
Switzerland during the study period (2014-2019). Only a
few patients in Switzerland take dabigatran (thus the
TABLE 2. Main Outcomes According to Prior Anticoagulation Therapy Among Ischemic Stroke Patients with
Atrial Fibrillation
Outcome Control VKA, all VKA (INR ≤1.7) VKA (INR >1.7) DOACs pa














β, 95% CI 1 [Reference] −0.91 (−1.53 to
−0.29)






No./Total No. 1,544/2,504 156/247 69/464 <0.001
Percentage (95% CI) 73.7% (71.6–75.7) 63.2%
(56.8–69.2)
14.9% (11.8–18.4)
aOR (95% CI) 1 [Reference] 0.67 (0.50–0.90) 0.06 (0.05–0.08)
Admission to IVT
start, min
n = 1,500 n = 164 n = 72 <0.001




sICH after IVT 0.796
Percentage (95% CI) 3.6% (2.6–4.7) 4.6% (1.9–9.2) 3.1% (0.4–10.8)




No./Total No. 726/1,707 168/304 170/394
Percentage (95% CI) 42.5% (40.2–44.9) 41.9%
(35.5–48.5)
43.1% (38.2–48.2)
sICH after MT 3.3% (2.5–4.2) 4.3% (2.1–7.8) 1.3% (0.4–3.0) 0.060
Functional outcome at 3 mo
mRS 0–2 at 3 mo
No./Total No. 1,753/3,113 477/879 171/ 348 306/531 597/992 0.004





aOR (95% CI) basicc 1 [Reference] 1.07 (0.90–1.28) 0.99 (0.77–1.28) 1.13 (0.91–1.41) 1.13 (0.95–1.34)
aOR (95% CI)
advancedd
1 [Reference] 1.13 (0.93–1.38) 1.01 (0.76–1.35) 1.22 (0.96–1.56) 1.24 (1.01–1.51)
aUnivariate comparison between controls, all VKAs (or VKA with INR ≤1.7 for acute recanalization therapy outcomes) and DOACs.
bAmong potentially eligible patients: for IVT: 0 to 4.5 hours after symptom onset and excluding patients with INR >1.7, platelet count <100 g/l,
admission glucose <2.7 mmol/l or >22.2 mmol/l, NIHSS <4 and patients with a history of intracerebral hemorrhage before ischemic stroke onset. For
MT: 0 to 6 hours after symptom onset and NIHSS ≥6.
cThe basic functional outcome model adjusts for baseline demographic and clinical variables before the index stroke event, including age, sex, admis-
sion NIHSS, use of IVT and endovascular treatment. Excludes 40% of records (3,195 with missing outcome and 102 missing adjustment values).
dThe advanced functional outcome model adjusts additionally for admission glucose, onset to admission time, previous ischemic stroke, previous intra-
cerebral hemorrhage, arterial hypertension, diabetes mellitus and systolic blood pressure. Excludes 50% of records (3,195 with missing outcome and
933 missing adjustment).
aOR = adjusted odds ratio; CI = confidence interval; DOACs = direct oral anticoagulants; INR = international normalized ratio; IQR = interquartile
range; IVT = intravenous thrombolysis; mRS = modified Rankin Scale; MT = mechanical thrombectomy; NIHSS = National Institutes of Health
Stroke Scale; sICH ECASS II = symptomatic intracranial hemorrhage according to the European Co-operative Acute Stroke Study-II definition;
VKA = vitamin K antagonist.
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absolut number of patients on dabigatran presenting with
stroke in Switzerland is low), and no center reported the
use of any reversal agent before IVT or MT.
The main reasons for withholding intravenous
thrombolysis in potentially eligible patients on DOACs
are presented in Table 3.
Functional Outcome at 3 Months
Information on the functional outcome at 3 months
(mRS) was available for 61% of patients (n = 4,984), with
no differences in availability between the groups
(p = 0.249). Patients on DOACs (60%) had the highest
unadjusted rates of favorable outcome at 3 months in
comparison to control patients (56%) and patients on
VKA (54%, p = 0.004; Fig 3). After adjustment for basic
confounders, no significant association of VKA (aOR
1.07, 95% CI 0.90–1.28) or DOACs (aOR 1.13, 95%
CI 0.95–1.34) with favorable outcome at 3 months was
found. After including additional confounders in the
advanced model, there was a significant association of
DOACs (aOR 1.24, 95% CI 1.01–1.51) but not VKAs
(aOR 1.13, 95% CI 0.93–1.38) with favorable outcome.
No significant interaction of IVT eligibility with DOACs
(p = 0.850) or VKA (p = 0.835) was seen regarding func-
tional outcome.
Post-hoc sensitivity analyses revealed that the results
of the main analysis were consistent if NIHSS was omit-
ted from the model (DOACs: basic model, aOR 1.20,
95% CI 1.03–1.41, p = 0.022; advanced model, aOR
1.34, 95% CI 1.12–1.61, p = 0.002) or if pre-stroke mRS
was included (DOACs: basic model, aOR 1.31, 95% CI
1.06–1.61, p = 0.011; advanced model, aOR 1.40, 95%
CI 1.11–1.77, p = 0.004). In a model using ordinal shift
analysis instead of dichotomized mRS, prior DOAC treat-
ment was associated with lower mRS at 3 months in the
advanced model (aOR 0.85, 95% CI 0.73–0.99,
p = 0.041) but not in the basic model (OR 0.93, 95% CI
0.81–1.06, p = 0.257).
Discussion
The main findings of this large, nationwide registry-based
study of ischemic stroke patients with AF and anti-
coagulation, in comparison to patients with AF without
anticoagulation (controls) were as follows: First, anti-
coagulation therapy before stroke onset was common
(13%) among all-cause stroke patients. Second, among
ischemic stroke patients with AF, the rate of prior anti-
coagulation was high (38%), representing a major chal-
lenge among those patients potentially eligible for IVT.
The number of patients on DOACs was increasing rapidly
throughout the study period. Third, prior DOAC therapy
was associated with decreased stroke severity, reduced rates
of LVO, and better functional outcome at 3 months when
compared with controls. Fourth, although there seem to
be no significant restrictions in the use of MT, DOAC
pretreatment represented a major barrier to initiation of
IVT: patients on DOACs had a 5-fold lower rate of IVT
than controls. Fifth, IVT in selected patients on DOACs
seemed safe when compared with patients on sub-
therapeutic VKA or controls.
Previous estimates indicated that ~1% of patients
eligible for IVT will be on a DOAC.27 However, the
number of patients being prescribed DOACs has increased
dramatically in recent years.28 Not only have they become
the first-line treatment for stroke prevention in patients
with non-valvular AF, but they are also prescribed for an
increasing number of additional indications.29 In accor-
dance with previous studies, we found that 1 in 8 of all
stroke patients had been on anticoagulation therapy.
However, in the subgroup of AF patients who are poten-
tially eligible for IVT, 1 in 4 patients had prior anti-
coagulation treatment. This finding, together with the
rapidly increasing numbers of patients on DOACs, under-
lines the importance of establishing safe and reliable man-
agement guidelines for recanalization treatments in this
population.
Consistent with our hypothesis, the rate of IVT was
markedly lower in patients on DOACs than in controls,
reflecting the uncertainty felt by clinicians about whether
to apply IVT in this clinical situation. Most Swiss stroke
units and stroke centers follow a dedicated standard oper-
ating procedure to guide treatment decisions. These use
FIGURE 3: Functional outcome at 3 months according to
prior anticoagulation treatment in patients with ischemic
stroke. The dark gray line indicates a significant association
of DOACs (aOR 1.24, 95% CI 1.01–1.51), but not VKA (light
gray line, aOR 1.13, 95% CI 0.93–1.38) with good functional
outcome (mRS 0–2). aOR = adjusted odds ratio; CI =
confidence interval; DOACs = direct oral anticoagulants;
mRS = modified Rankin Scale; VKA = vitamin K antagonist.
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TABLE 3. Reasons to Withhold Intravenous Thrombolysis in DOAC Patients and Possible Solutions
Reason to Withhold IVT Frequency (%) Possible Solution to Overcome This
DOAC plasma levels too high 23 At present, it is not known whether
patients who have therapeutic DOAC
plasma levels have an increased risk of
symptomatic intracranial hemorrhage
after thrombolyis compared with patients
without anticoagulation. International
collaboration to gather cases of
erroneously thrombolysed patients
despite high drug levels.
Establish not only safety, but also
efficacy of DOAC reversal for IVT,
ideally by a randomized controlled trial.
Stroke-related reasons with unclear risk–
benefit (ie, low NIHSS, almost 4.5 h
after onset, infarct demarcation or
regressive symptoms)
21 Not DOAC specific
DOAC measurement not available 14 Distribute DOAC test capacities in
hospitals providing IVT, especially in
smaller hospitals and during non-office
hours
Other patient-related reasons (ie,
palliative care decided on admission,
frailty, etc.)
11 Not DOAC specific
Turnaround for DOAC level too long 9 Establish rapid and reliable DOAC tests,
ideally point of care
Direct mechanical thrombectomy
preferred
8 Ongoing trials will clarify whether IVT
has additional benefits, but according to
first trials this seems reasonable
Uncertainity about cut-off values 5 Establish reliable cut-offs of DOAC
plasma levels, provided there is an
increased risk of symptomatic
intracranial hemorrhage in patients on
DOACs
Surrogate coagulation too high 3 Given that correlation of unspecific tests
with plasma levels is not sufficient, there
is a need to provide capacity to test for
specific drug levels and to ascertain
compliance reliably
Other contraindication for IVT 3 None
Certain compliance regardless of drug
levels
2 See DOAC plasma levels too high
Other suspected diagnosis on admission 1 Not DOAC specific
DOAC = direct oral anticoagulants; IVT = intravenous thrombolysis; NIHSS = National Institutes of Health Stroke Scale.
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drug-specific coagulation assays (in addition to time since
last intake) as recommended by recent guidelines and
expert opinion.26,30,31 Despite these efforts, the rate of
IVT was >5 times lower in patients on DOACs than in
controls.
The most frequent reason for withholding IVT was
a high DOAC plasma level, despite the fact that earlier
research found that among patients on rivaroxaban, the
plasma level was low in most patients at the time of
admission.32 It seems appropriate to withhold IVT in
those patients (primum non nocere), but it is unclear
whether IVT genuinely increases the risk of sICH in such
patients. Conclusive observational data of erroneously
thrombolyzed patients or the use of reversal agents (see
below) prior to IVT could overcome this barrier. The sec-
ond most common reason to withhold IVT was scenarios
in which the risk–benefit estimation was deemed uncer-
tain owing to low stroke severity, regressive symptoms,
late presentation, or imaging demarcation of the ischemia.
For such scenarios, it would also be of utmost importance
to clinicians to know whether they should factor therapeu-
tic DOAC therapy into this equation. Another relevant
factor was availability and cut-off values for DOAC spe-
cific coagulation assays, which require allocation of testing
capacities and identification of reliable cut-off values.
Reassuringly, there was no signal towards an
increased risk of sICH after application of IVT in patients
on DOACs in comparison to controls or patients on VKA
(INR ≤1.7). This is in line with published reports that
found no difference in the occurrence of sICH after IVT
in patients on DOACs in comparison to patients without
anticoagulation.19,33,34 However, the relative safety of
IVT in the setting of DOAC pretreatment probably
reflects cautious patient selection, because 80 to 90% of
patients on DOACs presenting within the thrombolysis
time window are not given IVT.18,35
The use of a drug-specific reversal agent before IVT
in patients on DOACs has emerged for dabigatran, using
idarucizumab.24,25,36 Although most Swiss centers have
considered this approach, owing to the low market share
of dabigatran in Switzerland, no Swiss hospital has
reported its use. Andexanet alfa was not available in Swit-
zerland during the study period, and studies are needed to
determine whether its use before IVT is safe and effective.
However, as shown by our study, there seems to be a large
proportion of patients who are potentially eligible for this
approach.
Previous studies have shown a reduction in stroke
severity in patients on therapeutic VKA8,37,38 and
DOAC9 therapy, but did not report any long-term out-
comes or explanations for this finding. Our results expand
these findings with almost identically reduced values for
NIHSS in the anticoagulation categories. Importantly, our
data might provide a plausible pathophysiological explana-
tion, because DOAC pretreatment was associated with
lower rates of LVO, which usually results in large, severe
strokes. Furthermore, our data indicate that the associa-
tion of stroke severity, when compared with controls,
might even be more pronounced in patients on DOACs
(~2 points less on the NIHSS) than in those on therapeu-
tic VKA (~1 point less on the NIHSS). However, the
temporal relationship between AF diagnosis and stroke
was not evident within the registry, and selection bias for
anticoagulation indication might have affected this obser-
vation. Other potentially causal factors, such as heart rate
control, cardiac output, and adjunctive treatments, might
modify stroke severity directly or by influencing thrombus
size. Ideally, a pooled analysis of recurrent stroke events in
randomized controlled trials could clarify whether DOACs
truly reduce stroke severity by lowering the rate of LVO
in comparison to VKA.
Our study is the first to report 3-month outcomes,
and our adjusted estimates indicate that DOAC pre-
treatment might be associated with favorable functional
outcome at 3 months. However, given the limitations dis-
cussed below, further observational studies are necessary
to confirm that this favorable association is real, because a
randomized controlled trial on pretreatment is impossible.
Finally, we did not find any significant influence of
the lower IVT rate among patients on DOACs on the
functional outcome at 3 months. However, this finding
has to be interpreted with caution because interaction ana-
lyses are known to be underpowered.39 Interestingly, rates
of MT did not differ among patients with prior DOACs,
VKAs, and controls. Although the lower rate of IVT
among patients on DOACs seems to have no impact on
overall outcomes at a population level, we cannot exclude
the possibility that withholding IVT for patients on
DOACs might have a significant influence on outcome at
an individual patient level.
Strengths and Limitations
Our study has several limitations. First, although data
were collected prospectively and independently, the statis-
tical analysis was retrospective and thus prone to bias. Sec-
ond, the standard operating procedure to select patients
on DOACs for IVT differed among centers. Third,
although we report data from a large, national dataset, the
study was underpowered to show a difference in 3-month
outcomes among patients treated with IVT, and we can-
not exclude the possibility that the lower rate of IVT in
patients on DOACs results in poor outcomes at an indi-
vidual patient level. Fourth, data completeness was good
to excellent for most outcomes, including NIHSS (98%),
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IVT/MT (99%), and sICH (98%), but there was a signif-
icant amount of missing data for 3-month outcomes
(61%). Selection bias, residual and unmeasured con-
founding, and attrition bias might therefore have
influenced the results regarding functional outcome of this
study. Fifth, thrombin time, an unspecific coagulation
assay that might help to guide treatment decisions in
patients on dabigatran, was not collected as part of the
Swiss stroke registry.
Nevertheless, our study has several strengths. We
used data from a national registry enrolling consecutive
patients in a prospectively constructed database with
predefined variables, which should limit selection bias.
Also, we included data from regional stroke units and
from tertiary academic and non-academic centers, which
means that our findings should be generalizable.
Summary and Conclusions
One in 8 ischemic stroke patients and 1 in 4 ischemic
stroke patients potentially eligible for IVT had prior anti-
coagulation treatment. Prior DOAC therapy was associ-
ated with decreased stroke severity, lower rates of LVO,
and a better functional outcome at 3 months when com-
pared with controls. DOAC pretreatment represents a bar-
rier to IVT initiation, although IVT seemed safe in
selected patients.
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